**Vertex Pharmaceuticals Faces Setbacks with Pain Drug Trials**
Vertex Pharmaceuticals Inc. experienced a decline in its stock value following disappointing results from an experimental pain medication and a lack of regulatory support for its broader use in chronic pain treatment. The company, which has been working to expand its portfolio beyond cystic fibrosis therapies, had high hopes for its non-opioid pain drug, Journavx, which received U.S. regulatory approval in January. This marked the introduction of the first new painkiller in over twenty years.
In premarket trading on Tuesday, Vertex shares dropped by as much as 14%. Despite this setback, the stock has risen 17% since the beginning of the year, as of Monday’s close. Vertex is also developing Journavx as a safer alternative to addictive opioids for chronic pain stemming from nerve damage. However, U.S. Food and Drug Administration (FDA) staff reviewing a study of the drug indicated that they do not foresee a pathway for its widespread use in this area at present, as stated in Vertex’s second-quarter earnings report.
The company is exploring other drugs in its pipeline to determine if they may offer better efficacy than Journavx. Additionally, Vertex announced that its experimental pain drug VX-993 failed to demonstrate significant benefits in a mid-stage study for acute pain, leading to the decision to halt its development as a standalone treatment.
RBC Capital Markets analyst Brian Abrahams noted that the recent FDA feedback and the failure of VX-993 should prompt a reevaluation of the overall opportunity and risk associated with Vertex’s pain franchise. The company plans to conduct a second trial of Journavx specifically for diabetic peripheral neuropathy, which represents 20% of the neuropathic pain market, while it will not proceed with a final study in a different condition.
Since its launch in early March, over 110,000 prescriptions for Journavx have been filled for acute pain conditions. However, the failure of VX-993 to provide statistically significant benefits for patients undergoing bunionectomy surgery raises concerns about the challenges Vertex may face in improving upon Journavx.
The FDA’s current stance limits Vertex’s potential to capture a significant share of the chronic pain market. Despite these challenges, the company reported second-quarter revenue and profits that exceeded analyst expectations and reaffirmed its full-year revenue outlook. In a leadership update, Chief Scientific Officer David Altshuler announced plans to retire on August 1, 2026, with Mark Bunnage, the current senior vice president of global research, set to succeed him on February 1.
**FAQ**
**What challenges is Vertex Pharmaceuticals facing with its pain drug?**
Vertex Pharmaceuticals is facing setbacks with its experimental pain drug Journavx, as recent FDA reviews indicate limited pathways for its use in chronic pain, alongside the failure of another drug, VX-993, in clinical trials.
